<font color="red">Safety_1</font> <font color="red">,_1</font> <font color="red">tolerability_1</font> <font color="red">,_1</font> and <font color="red">immunogenicity_1</font> after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age . 
<br>
<br> BACKGROUND Incidence and severity of herpes zoster ( HZ ) and postherpetic neuralgia increase with age , associated with age - related decrease in immunity to varicella - zoster virus ( VZV ) . One dose of zoster vaccine ( ZV ) has demonstrated substantial protection against HZ ; this study examined impact of a second dose of ZV . 
<br> METHODS Randomized , double - blind , multicenter study with 210 subjects ≥60 years old compared <font color="red">immunity_1</font> and <font color="red">safety_1</font> <font color="red">profiles_1</font> after one and two doses of ZV , separated by 6 weeks , vs. placebo . Immunogenicity was evaluated using <font color="red">VZV_1</font> <font color="red">interferon_1</font> <font color="red">-_1</font> <font color="red">gamma_1</font> <font color="red">(_1</font> <font color="red">IFN-γ_1</font> <font color="red">)_1</font> <font color="red">enzyme_1</font> <font color="red">-_1</font> <font color="red">linked_1</font> <font color="red">immunospot_1</font> <font color="red">(_1</font> <font color="red">ELISPOT_1</font> <font color="red">)_1</font> <font color="red">assay_1</font> and <font color="red">VZV_1</font> <font color="red">glycoprotein_1</font> <font color="red">enzyme_1</font> <font color="red">-_1</font> <font color="red">linked_1</font> <font color="red">immunosorbent_1</font> <font color="red">antibody_1</font> <font color="red">(_1</font> <font color="red">gpELISA_1</font> <font color="red">)_1</font> <font color="red">assay_1</font> <font color="red">._1</font> <font color="red">Adverse_1</font> <font color="red">experiences_1</font> <font color="red">(_1</font> <font color="red">AEs_1</font> <font color="red">)_1</font> were recorded on a standardized Vaccination Report Card . 
<br> RESULTS No serious vaccine - related <font color="red">AEs_1</font> occurred . <font color="red">VZV_1</font> <font color="red">IFN-γ_1</font> <font color="red">ELISPOT_1</font> <font color="red">geometric_1</font> <font color="red">mean_1</font> <font color="red">count_1</font> <font color="red">(_1</font> <font color="red">GMC_1</font> <font color="red">)_1</font> of spot - forming cells per 10(6 ) peripheral blood mononuclear cells increased in the ZV group from 16.9 prevaccination to 49.5 and 32.8 at 2 and 6 weeks postdose 1 , respectively . Two weeks , 6 weeks and 6 months postdose 2 , <font color="red">GMC_1</font> was 44.3 , 42.9 , and 36.5 , respectively . <font color="red">GMC_1</font> in the placebo group did not change during the study . The peak <font color="red">ELISPOT_1</font> response occurred ∼2 weeks after each ZV dose . The <font color="red">gpELISA_1</font> <font color="red">geometric_1</font> <font color="red">mean_1</font> <font color="red">titers_1</font> <font color="red">(_1</font> <font color="red">GMTs_1</font> <font color="red">)_1</font> in the ZV group were higher than in the placebo group at 6 weeks after each dose . Correlation between the <font color="red">IFN-γ_1</font> <font color="red">ELISPOT_1</font> and <font color="red">gpELISA_1</font> <font color="red">assays_1</font> was poor . 
<br> CONCLUSIONS ZV was generally well - tolerated and immunogenic in adults ≥60 years old . A second dose of ZV was generally safe , but did not boost VZV - specific immunity beyond levels achieved postdose 1 .